Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect

Pharmaceutical Research

Volumn 28, Issue 12, 2011, Pages 3189-3198

  Huynh, Ngoc Trinh ^a,b   Morille, Marie ^a,b   Bejaud, Jerome ^a,b   Legras, Pierre ^c   Vessieres, Anne ^d   Jaouen, Gerard ^d   Benoit, Jean Pierre ^a,b   Passirani, Catherine ^a,b  

^a LUNAM Universite   (France)

^b INSERM   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

ectopic; FcdiOH; orthotopic; PEGylated nanoparticles; stealth properties

Indexed keywords

ANTINEOPLASTIC AGENT; FERROCIPHENOL; LIPID NANOCAPSULE; MACROGOL; NANOCAPSULE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; FEMALE; GLIOSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS TISSUE; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; FERROUS COMPOUNDS; GLIOSARCOMA; LIPIDS; NANOCAPSULES; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED F344;

EID: 83555174437     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0501-y     Document Type: Article

References (45)

1. G Jaouen S Top A Vessieres R Alberto 2000 New paradigms for synthetic pathways inspired by bioorganometallic chemistry J Organomet Chem 600 1-2 23 36 10.1016/S0022-328X(00)00036-X 1:CAS:528:DC%2BD3cXltFClsr0%3D
2. A Vessieres S Top P Pigeon E Hillard L Boubeker D Spera, et al. 2005 Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro J Med Chem 48 12 3937 3940 15943467 10.1021/jm050251o 1:CAS:528:DC%2BD2MXktF2ltbc%3D (Pubitemid 40800602)
3. S Top A Vessieres G Leclercq J Quivy J Tang J Vaissermann, et al. 2003 Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines Chemistry 9 21 5223 5236 14613131 10.1002/chem.200305024 1:CAS:528:DC%2BD3sXpt1Cmtrw%3D
4. E Allard C Passirani E Garcion P Pigeon A Vessieres G Jaouen, et al. 2008 Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas J Control Release 130 2 146 153 18582507 10.1016/j.jconrel.2008.05.027 1:CAS:528: DC%2BD1cXhtVais7rO
5. A Nguyen V Marsaud C Bouclier S Top A Vessieres P Pigeon, et al. 2008 Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment Int J Pharm 347 1-2 128 135 17643877 10.1016/j.ijpharm.2007.06.033 1:CAS:528:DC%2BD2sXhtlOjsrjI (Pubitemid 350186087)
6. B Heurtault P Saulnier B Pech JE Proust JP Benoit 2002 A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm Res 19 6 875 880 12134960 10.1023/A:1016121319668 1:CAS:528:DC%2BD38XltVSgtrs%3D (Pubitemid 34692585)
7. NT Huynh C Passirani P Saulnier JP Benoit 2009 Lipid nanocapsules: a new platform for nanomedicine Int J Pharm 379 2 201 209 19409468 10.1016/j.ijpharm.2009.04.026 1:CAS:528:DC%2BD1MXhtVKjsr%2FF
8. E Allard NT Huynh A Vessieres P Pigeon G Jaouen JP Benoit, et al. 2009 Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model Int J Pharm 379 2 317 323 19467309 10.1016/j.ijpharm.2009.05.031 1:CAS:528:DC%2BD1MXhtVKjsr3J
9. A Vonarbourg C Passirani P Saulnier JP Benoit 2006 Parameters influencing the stealthiness of colloidal drug delivery systems Biomaterials 27 24 4356 4373 16650890 10.1016/j.biomaterials.2006.03.039 1:CAS:528:DC%2BD28XksFyns7g%3D (Pubitemid 43674179)
10. NT Huynh E Roger N Lautram JP Benoit C Passirani 2010 The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting Nanomedicine (Lond) 5 9 1415 1433 10.2217/nnm.10.113 1:CAS:528: DC%2BC3cXhsFWjs7jL
11. S Ballot N Noiret F Hindre B Denizot E Garin H Rajerison, et al. 2006 99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution Eur J Nucl Med Mol Imaging 33 5 602 607 16450136 10.1007/s00259-005-0007-0 1:CAS:528:DC%2BD28XktFSqsL4%3D
12. H Maeda J Wu T Sawa Y Matsumura K Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 1-2 271 284 10699287 10.1016/S0168-3659(99)00248-5 1:CAS:528: DC%2BD3cXhtl2qsLo%3D (Pubitemid 30122932)
13. M Morille T Montier P Legras N Carmoy P Brodin B Pitard, et al. 2010 Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting Biomaterials 31 2 321 329 19800113 10.1016/j.biomaterials.2009.09.044 1:CAS:528:DC%2BD1MXhtlOrtLjE
14. MC Papadopoulos S Saadoun DK Binder GT Manley S Krishna AS Verkman 2004 Molecular mechanisms of brain tumor edema Neuroscience 129 4 1011 1020 15561416 10.1016/j.neuroscience.2004.05.044 1:CAS:528:DC%2BD2cXhtVSlur%2FM (Pubitemid 39556252)
15. SC Steiniger J Kreuter AS Khalansky IN Skidan AI Bobruskin ZS Smirnova, et al. 2004 Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles Int J Cancer 109 5 759 767 14999786 10.1002/ijc.20048 1:CAS:528:DC%2BD2cXivFClu7Y%3D (Pubitemid 38405625)
16. Y Yamashita R Saito M Krauze T Kawaguchi C Noble D Drummond, et al. 2006 Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts Target Oncol 1 2 79 85 10.1007/s11523-006-0011-8 (Pubitemid 44072410)
17. E Corsini M Gelati C Calatozzolo G Alessandri S Frigerio M De Francesco, et al. 2004 Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization Cancer Immunol Immunother 53 11 955 962 15449042 10.1007/s00262-004-0529-5 1:STN:280:DC%2BD2cvnvFWnsQ%3D%3D (Pubitemid 39371740)
18. I Brigger J Morizet G Aubert H Chacun MJ Terrier-Lacombe P Couvreur, et al. 2002 Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting J Pharmacol Exp Ther 303 3 928 936 12438511 10.1124/jpet.102.039669 1:CAS:528:DC%2BD38Xptlamt70%3D (Pubitemid 35424373)
19. G Jaouen S Top A Vessières G Leclercq J Quivy L Jin, et al. 2000 The first organometallic antioestrogens and their antiproliferative effects Comptes Rendus de l'Academie des Sciences-Series IIc: Chemistry 3 2 89 93 10.1016/S1387-1609(00)00118-3 1:CAS:528:DC%2BD3cXksVGqsb8%3D
20. N Anton P Gayet JP Benoit P Saulnier 2007 Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion Int J Pharm 344 44 52 17592746 10.1016/j.ijpharm. 2007.04.027 1:CAS:528:DC%2BD2sXhtV2qtb7L (Pubitemid 47495984)
21. A Beduneau P Saulnier N Anton F Hindre C Passirani H Rajerison, et al. 2006 Pegylated nanocapsules produced by an organic solvent-free method: evaluation of their stealth properties Pharm Res 23 9 2190 2199 16952009 10.1007/s11095-006-9061-y 1:CAS:528:DC%2BD28XptVaisb0%3D
22. D Hoarau P Delmas S David E Roux JC Leroux 2004 Novel long-circulating lipid nanocapsules Pharm Res 21 10 1783 1789 15553223 10.1023/B:PHAM.0000045229. 87844.21 1:CAS:528:DC%2BD2cXos1WqtL0%3D (Pubitemid 39390089)
23. A Vonarbourg C Passirani L Desigaux E Allard P Saulnier O Lambert, et al. 2009 The encapsulation of DNA molecules within biomimetic lipid nanocapsules Biomaterials 30 18 3197 3204 19329183 10.1016/j.biomaterials.2009.03.009 1:CAS:528:DC%2BD1MXltVWjsLo%3D
24. J Hureaux F Lagarce F Gagnadoux MC Rousselet V Moal T Urban, et al. 2010 Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice Pharm Res 27 3 421 430 20054705 10.1007/s11095-009-0024-y 1:CAS:528:DC%2BC3cXisFansg%3D%3D
25. A Lamprecht JL Saumet J Roux JP Benoit 2004 Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment Int J Pharm 278 2 407 414 15196644 10.1016/j.ijpharm.2004.03.018 1:CAS:528:DC%2BD2cXkslKlsrk%3D (Pubitemid 38759512)
26. E Garcion A Lamprecht B Heurtault A Paillard A Aubert-Pouessel B Denizot, et al. 2006 A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats Mol Cancer Ther 5 7 1710 1722 16891457 10.1158/1535-7163.MCT-06-0289 1:CAS:528:DC%2BD28XnslWksLo%3D (Pubitemid 44323239)
27. A Vonarbourg C Passirani P Saulnier P Simard JC Leroux JP Benoit 2006 Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake J Biomed Mater Res A 78 3 620 628 16779767 1:STN:280:DC%2BD28rgslSmtQ%3D%3D (Pubitemid 44253547)
28. C Passirani G Barratt JP Devissaguet D Labarre 1998 Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system Life Sci 62 8 775 785 9489513 10.1016/S0024-3205(97)01175-2 1:CAS:528:DyaK1cXmtFeltQ%3D%3D (Pubitemid 28062593)
29. S Tsuchiya Y Kobayashi Y Goto H Okumura S Nakae T Konno, et al. 1982 Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester Cancer Res 42 4 1530 1536 6949641 1:CAS:528:DyaL38Xks1OmsLw%3D (Pubitemid 12148801)
30. A Vonarbourg P Saulnier C Passirani JP Benoit 2005 Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface Electrophoresis 26 11 2066 2075 15852355 10.1002/elps.200410145 1:CAS:528:DC%2BD2MXls1GltLg%3D (Pubitemid 40852638)
31. J Park PM Fong J Lu KS Russell CJ Booth WM Saltzman, et al. 2009 PEGylated PLGA nanoparticles for the improved delivery of doxorubicin Nanomedicine 5 4 410 418 19341815 10.1016/j.nano.2009.02.002 1:CAS:528:DC%2BC3cXls1ektQ%3D%3D
32. G Mattheolabakis E Taoufik S Haralambous ML Roberts K Avgoustakis 2009 In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles Eur J Pharm Biopharm 71 2 190 195 18929649 10.1016/j.ejpb.2008.09.011 1:CAS:528:DC%2BD1MXitVShsL0%3D
33. WC Zamboni S Ramalingam DM Friedland RP Edwards RG Stoller S Strychor, et al. 2009 Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies Clin Cancer Res 15 4 1466 1472 19190127 10.1158/1078-0432.CCR-08-1405 1:CAS:528:DC%2BD1MXitVOktLg%3D
34. Passirani C, Benoit JP. Complement activation by injectable colloidal drug carriers. In: Mahato RI, editor. Biomaterials for delivery and targeting of proteins and nucleic acids. Boca Raton: CRC; 187. p. 230-2005.
35. F Yuan X Qin D Zhou QY Xiang MT Wang ZR Zhang, et al. 2008 In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates Eur J Pharm Biopharm 70 3 770 776 18656539 10.1016/j.ejpb.2008.06.028 1:CAS:528:DC%2BD1cXhtlagsL7N
36. DL Emerson R Bendele E Brown S Chiang JP Desjardins LC Dihel, et al. 2000 Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan Clin Cancer Res 6 7 2903 2912 10914740 1:CAS:528:DC%2BD3cXlslenur8%3D (Pubitemid 30482133)
37. R Suzuki T Takizawa Y Kuwata M Mutoh N Ishiguro N Utoguchi, et al. 2008 Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome Int J Pharm 346 1-2 143 150 17640835 10.1016/j.ijpharm.2007.06.010 1:CAS:528:DC%2BD2sXhtlWmsLnP (Pubitemid 350101994)
38. K Kawano M Watanabe T Yamamoto M Yokoyama P Opanasopit T Okano, et al. 2006 Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles J Control Release 112 3 329 332 16678929 10.1016/j.jconrel. 2006.03.012 1:CAS:528:DC%2BD28XkvVWktrY%3D
39. S Murphy RA Davey XQ Gu MC Haywood LA McCann LE Mather, et al. 2007 Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model J Neurooncol 85 2 181 189 17534579 10.1007/s11060-007-9406-3 1:CAS:528: DC%2BD2sXhtl2gs73J (Pubitemid 47629399)
40. WM Pardridge 2005 The blood-brain barrier: bottleneck in brain drug development NeuroRx 2 1 3 14 15717053 10.1602/neurorx.2.1.3 (Pubitemid 40128022)
41. MB Segal 2000 The choroid plexuses and the barriers between the blood and the cerebrospinal fluid Cell Mol Neurobiol 20 2 183 196 10696509 10.1023/A:1007045605751 1:STN:280:DC%2BD3c7mtFCquw%3D%3D (Pubitemid 30091455)
42. US Sharma A Sharma RI Chau RM Straubinger 1997 Liposome-mediated therapy of intracranial brain tumors in a rat model Pharm Res 14 8 992 998 9279878 10.1023/A:1012136925030 1:CAS:528:DyaK2sXlslejtL0%3D (Pubitemid 27371396)
43. CH Heldin K Rubin K Pietras A Östman 2004 High interstitial fluid pressure-An obstacle in cancer therapy Nat Rev Cancer 4 10 806 813 15510161 10.1038/nrc1456 1:CAS:528:DC%2BD2cXos1ymu7s%3D (Pubitemid 39331152)
44. B Blouw H Song T Tihan J Bosze N Ferrara HP Gerber, et al. 2003 The hypoxic response of tumors is dependent on their microenvironment Cancer Cell 4 2 133 146 12957288 10.1016/S1535-6108(03)00194-6 1:CAS:528:DC%2BD3sXntFegtbg%3D (Pubitemid 37040829)
45. MR Machein KH Plate 2000 VEGF in brain tumors J Neurooncol 50 1-2 109 120 11245271 10.1023/A:1006416003964 1:STN:280:DC%2BD3Mzmsl2lsQ%3D%3D (Pubitemid 32166295)